Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-11T08:20:36.164Z Has data issue: false hasContentIssue false
  • English
  • Français

New insights into the mechanism of drug-induced dyskinesia

Published online by Cambridge University Press:  20 December 2012

Anton J. M. Loonen  and
Svetlana A. Ivanova
Anton J. M. Loonen*
Affiliation:
Department of Pharmacy, University of Groningen, Groningen, The Netherlands
Svetlana A. Ivanova
Affiliation:
Mental Health Research Institute, Siberian Branch Russian Academy Medical Sciences, Tomsk, Russian Federation
*
*Address for correspondence: Prof. Anton J. M. Loonen, Department of Pharmacy, Antonius Deusinglaan 1, 9713AV Groningen, The Netherlands. (Email a.j.m.loonen@rug.nl)
Get access Rights & Permissions [Opens in a new window]

Abstract

Dyskinesia is an extrapyramidal movement disorder characterized by involuntary, repetitive, irregular motions that affect the mouth and face and/or the limbs and trunk. Tardive dyskinesia (TD) is a well-known complication of long-term treatment with antipsychotic drugs. Dyskinesia is also induced with levodopa, a treatment for Parkinson's disease, and it occurs spontaneously as a symptom of Huntington's disease. Research on the pathogenesis of TD has focused on a dysfunction of either the dopaminergic or serotonergic system. However, recent evidence has suggested that we should focus on the possible damage of GABAergic medium spiny neurons (MSNs). MSNs are the first station in the cortico-striato-thalamo-cortical circuit that regulates the amplitude and velocity of movements. Two pathways can be distinguished in this circuit: a direct pathway, which increases movements (hyperkinesia), and an indirect pathway, which decreases movements (hypokinesia). Both pathways are activated by glutamatergic corticostriatal neurons. Here, we discuss some evidence that supports the hypothesis that indirect pathway MSNs are damaged in dyskinesia.

Keywords

dyskinesiamechanismlevodopamedium spiny neurons
Type
Opinion
Information
CNS Spectrums , Volume 18 , Issue 1 , February 2013 , pp. 15 - 20
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Lance, JW, McLeod, JG. A Physiological Approach to Clinical Neurology. London: Butterworth; 1970.Google Scholar
2.Groenewegen, HJ. The basal ganglia and motor control. Neural Plast. 2003; 10(1–2): 107–120.CrossRefGoogle ScholarPubMed
3.Groenewegen, HJ, Trimble, M. The ventral striatum as an interface between the limbic and motor systems. CNS Spectr. 2007; 12(12): 887–892.CrossRefGoogle ScholarPubMed
4.Stahl, SM. Essential Psychopharmacology. Cambridge, UK: Cambridge University Press; 2008.Google Scholar
5.Bashir, ZO. On long-term depression induced by activation of g-protein coupled receptors. Neurosci Res. 2003; 45(4): 363–367.Google ScholarPubMed
6.Loonen, AJ. Het beweeglijke brein. Badhoevedorp, the Netherlands: Mension; 2004.Google Scholar
7.Loonen, AJ, van Praag, HM. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol. 2007; 27(5): 423–430.CrossRefGoogle ScholarPubMed
8.Kane, JM. Tardive dyskinesia circa 2006. Am J Psychiatry. 2006; 163(8): 1316–1318.CrossRefGoogle ScholarPubMed
9.Margolese, HC, Chouinard, G, Kolivakis, TT, Beauclair, L, Miller, R. Tardive dyskinesia in the era of typical and atypical antipsychotics, part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005; 50(11): 541–547.CrossRefGoogle ScholarPubMed
10.Novak, MJ, Tabrizi, SJ. Huntington's disease. BMJ. 2010; 340(4): c3109.CrossRefGoogle ScholarPubMed
11.Thanvi, B, Lo, N, Robinson, T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007; 83: 384–388.CrossRefGoogle ScholarPubMed
12.Estrada Sanchez, AM, Mejia-Toiber, J, Massieu, L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res. 2008; 39(3): 265–276.CrossRefGoogle ScholarPubMed
13.Fan, MM, Raymond, LA. N-Methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2007; 81(5–6): 272–293.CrossRefGoogle ScholarPubMed
14.Kumar, P, Kalonia, H, Kumar, A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep. 2010; 62(1): 1–14.CrossRefGoogle ScholarPubMed
15.Arning, L, Kraus, PH, Valentin, S, etal. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics. 2005; 6(1): 25–28.CrossRefGoogle ScholarPubMed
16.Andresen, JM, Gayan, J, Cherny, SS, etal. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet. 2007; 44(1): 44–50.CrossRefGoogle ScholarPubMed
17.Arning, L, Saft, C, Wieczorek, S, etal. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet. 2007; 122(2): 175–182.CrossRefGoogle Scholar
18.Ivanova, SA, Loonen, AJ, Pechlivanoglou, P, etal. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry. 2012; 2(Jan 10): e67.CrossRefGoogle ScholarPubMed
19.Lohr, JB, Kuczenski, R, Niculescu, AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003; 17(1): 47–62.CrossRefGoogle ScholarPubMed
20.Al Hadithy, AF, Ivanova, SA, Pechlivanoglou, P, etal. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol. 2010; 25(1): 84–91.CrossRefGoogle ScholarPubMed